



uniQure to Participate in Multiple Upcoming Industry Conferences

March 1, 2019

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 01, 2019 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March:

- **Leerink Global Health Care Conference in New York City**

- [Matt Kapusta](#), chief executive officer at uniQure, will participate in a fireside chat on Friday, March 1 at 9:30 a.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.

- **Cowen & Co. Healthcare Conference in Boston, Mass.**

- [Matt Kapusta](#) will present a corporate update on Tuesday, March 12 at 10:40 a.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.

- **Barclays Healthcare Conference in Miami, Florida**

- [Sander van Deventer](#), M.D., Ph.D., chief scientific officer at uniQure, will present a corporate update and participate in a fireside chat on Wednesday, March 13 at 1:35 p.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.

- **BioCapital Europe by LSP in Amsterdam, the Netherlands**

- [Christian Klemt](#), chief accounting officer at uniQure, will present a corporate update on Thursday, March 14 at 2:30 p.m. CET.

- **Gene Therapy for Rare Disorders Conference in Boston, Mass.**

- Daniel Leonard, senior director of global patient advocacy at uniQure, will participate in the panel discussion "Patient Advocacy in the Gene Therapy Space: A Case Study in Hemophilia" on Wednesday, March 27 at 5:30 p.m. ET.
- [Jonathan Garen](#), chief business officer at uniQure, will present "The Emerging Business Models for Commercializing Gene Therapy Treatment for Hemophilia" on Thursday, March 28 at 11 a.m. ET.

- **Cold Spring Harbor Conference on RNA and Oligonucleotide Therapeutics in Cold Spring Harbor, NY**

- Melvin Evers, Ph.D., associate director of emerging technologies at uniQure, will present "Development of microRNA-based gene therapy for Huntington's disease" at the conference on Thursday, March 28.
- Marina Sogorb-Gonzalez, Ph.D. student at uniQure, will also present "Transfer of therapeutic miRNAs within extracellular vesicles secreted from Huntington's disease iPSC-derived neurons" at the conference, which takes place March 27-30.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and other severe genetic diseases. www.uniQure.com

uniQure Contacts

For Investors:

Maria E. Cantor

For Media:

Eva M. Mulder

Tom Malone

Direct: 339-970-7536

Direct: +31 20 240 6103

Direct: 339-970-7558